Diabetes
Conditions
Interventions
Empagliflozin Group:Metformin+Empagliflozin
Liraglutide Group:Metformin+Liraglutide
traditional treatment Group:Metformin+traditional oral hypoglycemic agents
Sponsors
Sichuan Academy of Medical Sciences•Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Patients voluntarily participated in the experiment and signed Informed consent; (2) Age between 18-70 years old; (3) BMI>=24kg/m2; (4) Newly diagnosed patients with type 2 diabetes have not been treated with hypoglycemic agents before; (5)HbAc<9%
Exclusion criteria
Exclusion criteria: (1) Patients with serious chronic diabetic complications, such as diabetic nephropathy, diabetic foot and diabetic macroangiopathy; (2) Patients with acute diabetic complications, include ketoacidosis, hyperosmotic coma and lactic acidosis; (3) Patients with serious concomitant diseases, such as liver and kidney dysfunction, heart failure and acute myocardial infarction; (4) Type 1 diabetes, gestational diabetes, adult onset juvenile diabetes and mitochondrial diabetes; (5) Tumor patients; (6) Pregnancy or lactation; (7) Patients who have used hypoglycemic agents before; (8) Patients in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c;Index Matsuda; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood glucose;insulin;C peptide; | — |
Countries
China
Contacts
Public ContactZhang Min
Sichuan Academy of Medical Sciences/Sichuan Provincial People's Hospital
Outcome results
None listed